27.12.2019

Transforming your pharma brand strategy: Building partnerships

By Luke Wilson

Transforming your pharma brand strategy: Building partnerships

If you could learn about who HCPs engage with or who they are influenced by then you could build relationships and partnerships with organisations that are already established in HCPs’ trusted networks. 

Our study of HCP conversations about pancreatic cancer showed that HCPs were most engaged with their peers. Beyond other HCPs, however, patient advocacy groups (PAGs) were also highly engaged, with the top two being PanCAN and Let’s Win! Pancreatic Cancer. HCPs shared, mentioned and interacted with these groups, reflecting the trust that exists between them. The data suggests that manufacturers who successfully engage with these organisations in a meaningful way have the opportunity to reach HCPs too.

An example of successful digital engagement can be seen in Celgene’s initiative to launch a hashtag, #PancChat, together with patient advocacy group Let’s Win! Pancreatic Cancer’s co-founder Allyson Ocean, in 2016.

This hashtag continues to bring together patients and HCPs in an online conversation to this day; the chart below illustrates how #PancChat has been a key driver of the online HCP conversation around pancreatic cancer. Each orange dot indicates a #PancChat discussion which HCPs use to engage with one another, patients and PAGs.

Read the next article in the series:

Transforming your pharma brand strategy: Digital Opinion Leaders

Transforming your pharma brand strategy: Digital Opinion Leaders

Read article

To understand how HCP insights could support your brand, download the complete white paper or get in touch.

 

View all articles >

Meet the Author

Luke Wilson

Suggested next


02.12.2020 | Article

Top 50 Pharma Tracker: Vaccine success dwarfs all other conversation

Discover what healthcare professionals (HCPs) think about Top 50 Pharmaceutical companies

By Mary Kangley

06.06.2022 | Article

Product Launch Tracker: HCPs excited by approvals for Eli Lilly, Novartis, Sanofi and Regeneron

Over the last month, HCPs discussed product approvals for the treatment of a variety...

By Paul Cranston and Tomi Shobande

View all articles >

Creation.co Logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.